Are FDA Panel Votes on Psych Drugs Tainted by Public Speakers’ COI?

February 7, 2020

(Medscape) – Members of the public who receive travel and other expenses from pharmaceutical study sponsors to attend US Food and Drug Administration (FDA) advisory panel meetings and provide testimony about the efficacy of a new psychiatric drug are highly likely to deliver a positive opinion, new research shows. Such individuals, investigators say, have the potential to skew outcomes of FDA advisory panel votes, potentially leading to psychiatric drug approvals that are not exclusively based on objective scientific evidence.